NCT05198427

mTOR Inhibitors: the Lesions Induced by Papillomavirus for Transplant Patients.

Study MOTIF : mTOR Inhibitors: the Lesions Induced by Papillomavirus for Transplant Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 45 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The injuries induced by Human Papillomavirus (HPV) (anogenital condyloma mainly) are more frequent among transplanted patients due to their immunosuppression. These injuries are benign but they have a negative impact on the patients' quality of life. The initial treatment is topical and then surgical. The injuries can relapse, especially among transplanted patients. The modification of the immunosuppressant treatment with a switch to mTOR inhibitors (mammalian Target Of Rapamycin) has shown its efficacy in preventing the recurrence of squamous cell carcinomas or treating Kaposi's disease. By analogy, this therapeutic strategy can be sometimes put forward to transplanted patients with HPV-induced injuries. The principal objective of this study is to describe the evolution of HPV-induced lesions in solid organ transplant patients.

Conditions

• Transplantation Organ

Interventions

Type	Name	Description
OTHER	review of medical patient file	The outcome measure is the evolution of HPV related lesions between : * favourable evolution including partial or total regression * unfavourable evolution including non-evolution or aggravation or recurrence.

Timeline

• Start date: 2022-02-14
• Primary completion: 2022-03-31
• Completion: 2022-03-31
• First posted: 2022-01-20
• Last updated: 2022-04-14

Locations

1 site across 1 country: France